Similar articles for PMID: 18977255

Year	Number of Results
1948	1
1976	1
1985	1
1987	1
1996	1
1998	1
1999	4
2000	2
2001	3
2002	7
2003	5
2004	9
2005	10
2006	14
2007	21
2008	21
2009	19
2010	25
2011	22
2012	49
2013	50
2014	46
2015	43
2016	40
2017	32
2018	26
2019	10
2020	17
2021	12
2022	10
2024	0

1

A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.

Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC. Jin CH, et al. J Control Release. 2009 Feb 10;133(3):172-7. doi: 10.1016/j.jconrel.2008.09.091. Epub 2008 Oct 21. J Control Release. 2009. PMID: 18977255

2

Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.

Chae SY, Jin CH, Shin HJ, Youn YS, Lee S, Lee KC. Chae SY, et al. Bioconjug Chem. 2008 Jan;19(1):334-41. doi: 10.1021/bc700292v. Epub 2007 Dec 14. Bioconjug Chem. 2008. PMID: 18078308

3

Biological activity of AC3174, a peptide analog of exendin-4.

Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM. Hargrove DM, et al. Regul Pept. 2007 Jun 7;141(1-3):113-9. doi: 10.1016/j.regpep.2006.12.021. Epub 2007 Jan 11. Regul Pept. 2007. PMID: 17292977

4

Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation.

Youn YS, Chae SY, Lee S, Kwon MJ, Shin HJ, Lee KC. Youn YS, et al. Eur J Pharm Biopharm. 2008 Mar;68(3):667-75. doi: 10.1016/j.ejpb.2007.07.009. Epub 2007 Aug 2. Eur J Pharm Biopharm. 2008. PMID: 17904340

5

PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.

Youn YS, Jeon JE, Chae SY, Lee S, Lee KC. Youn YS, et al. Diabetes Obes Metab. 2008 Apr;10(4):343-6. doi: 10.1111/j.1463-1326.2007.00823.x. Epub 2007 Nov 22. Diabetes Obes Metab. 2008. PMID: 18034839

6

The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics.

Chae SY, Choi YG, Son S, Jung SY, Lee DS, Lee KC. Chae SY, et al. J Control Release. 2010 May 21;144(1):10-6. doi: 10.1016/j.jconrel.2010.01.024. Epub 2010 Jan 20. J Control Release. 2010. PMID: 20093159

7

Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives.

Son S, Chae SY, Kim CW, Choi YG, Jung SY, Lee S, Lee KC. Son S, et al. J Med Chem. 2009 Nov 12;52(21):6889-96. doi: 10.1021/jm901153x. J Med Chem. 2009. PMID: 19827752

8

An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.

Baggio LL, Huang Q, Cao X, Drucker DJ. Baggio LL, et al. Gastroenterology. 2008 Apr;134(4):1137-47. doi: 10.1053/j.gastro.2008.01.017. Epub 2008 Jan 11. Gastroenterology. 2008. PMID: 18313669

9

Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.

Nakashima R, Yano T, Ogawa J, Tanaka N, Toda N, Yoshida M, Takano R, Inoue M, Honda T, Kume S, Matsumoto K. Nakashima R, et al. Eur J Pharmacol. 2014 Aug 15;737:194-201. doi: 10.1016/j.ejphar.2014.05.014. Epub 2014 May 22. Eur J Pharmacol. 2014. PMID: 24858371

10

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.

Wang Q, Brubaker PL. Wang Q, et al. Diabetologia. 2002 Sep;45(9):1263-73. doi: 10.1007/s00125-002-0828-3. Epub 2002 Apr 26. Diabetologia. 2002. PMID: 12242459

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

436 results

Results by year